StockWatch
·

INDOCO REMEDIES LTD. Q2 FY27 Results

INDOCOQ2 FY27 Results
Filing
Result:Weak· Market: Flat#One-off gain

Outlook: Cautiously Optimistic · Guidance: Maintained

MetricValue (₹ Cr)Q1 FY27Q2 FY26
Revenue520.1711.3%7.3%
Total Income522.1411.2%7.6%
Expenditure535.099.4%7.4%
PBT24.1968.9%278.8%
Net Profit19.4770.3%311.4%
OPM16.07%13.53pp7.30pp
NPM3.73%10.20pp5.63pp
EPS2.1170.2%111.0%
View full financials

Pharma's core profit metric shows the reported loss-to-profit swing is driven entirely by a one-off property-sale gain, while the adjusted pre-exceptional business remained in a near-identical loss (-₹12.95 Cr vs -₹13.00 Cr) with flat margins and revenue growth trailing management's own 12-15% target.

INDOCO REMEDIES · Q2 FY27 · THE VERDICT

Revenue milestone, margin collapse—execution risk rises

Indoco crossed ₹500 Cr quarterly revenue, but net profit crashed 70% quarter-on-quarter to ₹19.5 Cr. Management promised margin improvement; the quarter delivered the opposite. The gap between the headline and the guidance is the story.

29 Oct 2026 · 6 min read
Reported revenue

₹520.2 Cr

+7.3% YoY, +11.3% QoQ

Reported PAT

₹19.5 Cr

NPM 3.7% · -70.2% QoQ

EBITDA margin

9.2%

vs 10.3% prior · -110 bps

Implied Q1 PAT

~₹65 Cr

calculated back from QoQ -70%

The quarter opens clean: revenue crossed ₹500 Cr, a milestone. YoY growth of 7.3% is solid, and international formulations powered an 12.1% climb. But the profit line tells a different story. Net profit of ₹19.5 Cr—an NPM of just 3.7%—represents a brutal 70% sequential collapse from the implied Q1 figure of ~₹65 Cr. When management entered the previous call, it had guided for margin improvement quarter-on-quarter. Instead, EBITDA margin compressed 110 basis points from 10.3% to 9.2%. That gap—between guided and delivered—is where the earnings quality risk lives.

The freight shock and what it masks

On the call, management quantified a ₹13 crore freight headwind in Q2. COGS inflation of roughly 30% across solvents, raw materials, and logistics contributed another layer of pressure. These are external forces—geopolitical, not operational. The explanation is credible: Indoco's international exposure (173 crore in Q2 formulations revenue) means every shipping rate spike hits harder than a domestic-only peer. Freight is a temporary tailwind or headwind; it normalizes. The risk, though, is execution: margin recovery depends on new product launches landing and pricing power holding. The call hinted at 100 basis points of incremental EBITDA per ₹100 crore of new product revenue—a meaningful lever—but timelines remained opaque. Management refused to quantify launch timing ('not at this stage'), which limits visibility.

PAT by quarter, ₹ Cr (implied / reported)
-86.42-30.5425.3481.2265Q1 FY27 (implied)19.5Q2 FY27 (reported)-70.2QoQ change
The 70% sequential decline is the steepest move in the data. Freight and COGS inflation blamed, but execution risk on margin recovery is now evident.

Management's claims vs. what holds up

Grading Q2 statements against the delivered result

Consolidated revenue ₹506.9 Cr, growth 7.4%

Delivered ₹520.2 Cr, YoY 7.3%. Transcript understates by ₹13.3 Cr (2.6% gap).

Slightly overstated

Margins expected to improve Q-on-Q

Delivered: QoQ PAT -70.2%, EBITDA 9.2% vs 10.3% prior (down 110 bps).

Contradicted

Freight impact quantified at ₹13 Cr

Consistent with 30% COGS inflation noted. Plausible magnitude for international-heavy mix.

Supported

Regulated markets 20%+ growth; emerging 20%+ growth

Regulated (EU/UK) 21.1% ✓. Emerging only 12% due to ophthalmology exit (₹10 Cr revenue lost). Mixed execution vs aspiration.

Mixed

Debt reduction ₹110 Cr on track for FY27

H1 repaid ₹40–50 Cr consolidated. Paces to ₹110 Cr for full year if maintained.

Supported

What changed on this call

Warren Remedies API/OTC separation now formalized. Management registered Warren Life Sciences as a separate subsidiary to track API (early-stage, not yet profitable) and toothpaste (OTC, ~₹36 Cr Q2 revenue, near-breakeven after marketing pullback) separately. This is a structural shift—clearer accounting, but also a signal that integration is moving slower than expected. Toothpaste losses (~₹18 Cr annual drag) persist; management is reducing ad spend and expecting improvement with 'strategic focus and trade expansion,' but the timeline is vague.

Ophthalmology exit completed. The Sunways portfolio (ophthalmology products) was divested, removing ~₹10 Cr of emerging market revenue. This explains the gap between the emerging market growth aspiration (20%+) and the Q2 actual (12%). Emerging markets are cyclical—management cited Q1 miss and Q2 recovery, expecting H2 catch-up—but the exit cost visibility and raises questions about portfolio discipline in the emerging space.

Margin improvement guidance implicitly withdrawn. Prior call promised Q-on-Q margin gains. This call offers no margin guidance and instead leans on 'freight normalization' and 'new product uplift' as recovery levers. The tone shifted from bullish to cautious. No numeric FY27 revenue guidance was restated; management affirmed 12–15% CAGR aspiration long-term and 'high single-digit' domestic growth near-term, but declined to quantify product launch timing or a bounce-back quarter.

Street positioning: the post-result tape

The stock trades at ₹213.75 on a neutral trend (RSI 36.7, below all key SMAs: ₹236.99 20d, ₹241.5 50d, ₹222.33 200d). It sits 59.7% below its all-time high of ₹530.25, though +31.8% off the 52-week low. Volume is decreasing—a sign of waning retail interest. Institutional positioning shows a modest uptick: FII ownership rose to 1.27% from 0.94% q/q, a 33 bps gain, while domestic institutions held at ~18%. Promoter ownership remains static at 58.95%. Bulk block activity over the past six months clusters around ₹273–277, with trading firms (NK Securities, JunoMoneta, MicroCurves) cycling in and out—no promoter or insider selling signal. The market has priced in the weakness (down 60% from ATH), but the post-result tone is tepid. The margin miss and execution risk are headwinds; the long-term vision is not yet re-priced as a buyable dip.

Bull-bear ledger
  • Crossed ₹500 Cr quarterly revenue milestone

  • Regulated markets growing 21.1%, EU/UK order backlog steady

  • ~₹100 Cr MAT new products launched in past 2 years (growth lever)

  • Cyclopam ₹200 Cr brand, #2 anti-spasmodic, growing 30% YoY

  • Debt reduction ₹40–50 Cr H1, on track for ₹110 Cr FY27 target

  • Margin improvement guidance missed (QoQ PAT -70%, EBITDA -110 bps)

  • FPP (Warren toothpaste) losses ~₹18 Cr annually, breakeven delayed

  • Domestic standalone growth anemic (+2%), acute therapies weak

  • Emerging markets lagging 20%+ target (only 12% after ophthalmology exit)

  • FDA audit (7 observations) resolution uncertain (expected Dec 2026)

  • New product launch timing opaque; no visibility into margin recovery pace

Risks, ranked by how much they should concern a holder

Margin recovery execution

High

Q2 PAT down 70% despite 11% revenue growth. Prior guidance promised improvement; delivered worse. New products are the lever, but timelines are vague and regulatory approvals are gating. If launches slip, margins stay depressed into H2.

FDA audit and regulatory timelines

Medium

7 observations at Goa plant; resubmission expected Dec 2026. Resolution could delay product approvals and capacity expansion (Goa 2 de-risking). US API audit expected Feb 2027. A surprise DI/data integrity observation could halt export growth.

FPP (Warren) profitability drag

Medium

Toothpaste losses ~₹18 Cr annually on ₹36 Cr revenue. API early-stage, not yet profitable. Management is reducing ad spend but profitability timeline is unclear. If losses persist, they will offset domestic and regulated market gains.

Emerging market underperformance and cycles

Medium

Emerging growing only 12% vs 20%+ target. Ophthalmology exit cost ₹10 Cr revenue. Cycles and portfolio churn are structural; management expects Q3–Q4 catch-up, but execution has been weak. Missing emerging growth targets pressures the 12–15% CAGR ambition.

Domestic growth stalling

Medium

Standalone domestic +2% YoY. Acute therapies (Febrex, ATL) are down; Cyclopam +30% is offsetting but not enough. Portfolio rebalancing toward new products is the play, but visibility is low. If domestic doesn't accelerate in H2, consolidated growth grinds lower.

Freight and COGS inflation persistence

Low-Medium

₹13 Cr freight impact Q2; COGS inflation 30%. These are external and temporary (geopolitical/supply chain), but if normalization is delayed past H2, margin recovery is pushed into FY28. Already front-loaded pressure into Q2.

What to watch next

The 2–3 catalysts that resolve the debate
  • 1 · Q3 margin recovery and new product traction (Dec 2026 result)

    Will EBITDA margins bounce back above 10%? Will new product launches show up in Q3 segment revenue and drive 100+ bps incremental margin as promised? Freight normalization + product uplift is the base case; prove it. If Q3 PAT is still depressed (below ₹40 Cr), execution risk escalates.

  • 2 · FDA Goa plant audit resolution (expected Dec 2026)

    7 observations outstanding. A clean resubmission is expected, but a DI/data integrity surprise could halt exports. This is a gate on regulated market expansion momentum (21% growth today). Monitor the Dec resubmission outcome closely.

  • 3 · Domestic and emerging market acceleration in H2 (Q3–Q4)

    Management expects emerging markets to recover in Q3–Q4 after Q1 miss. Domestic needs to accelerate beyond +2% to support the 12–15% CAGR target. Watch segment revenue breakdown (domestic vs international, emerging vs regulated) for evidence of rebalancing. If both remain flat, the long-term story loses credibility.

Earnings quality and the ₹13 Cr gap

One accounting flag: the call transcript reports consolidated revenue of ₹506.9 Cr; the delivered result shows ₹520.2 Cr. The 2.6% gap (₹13.3 Cr) is material. Possible explanations include scope differences (subsidiaries, consolidation adjustments, or segment restatements), but management did not address the discrepancy on the call. Similarly, the NPM-to-OPM gap is large: OPM 16.1% but NPM only 3.7%, a 12.4 percentage-point spread. This suggests tax, finance costs, or consolidation adjustments are eating into profit. The call hinted at ₹96 Cr in other income, which could explain some of the gap if non-operating gains are material, but the data doesn't isolate those items clearly. These gaps warrant a clarification in next quarter's filings or call.

Indoco is a steady franchise with real long-term vision (12–15% CAGR, emerging/regulated growth, export doubling, debt reduction). The Q2 result proves it can scale to ₹500 Cr quarterly. But near-term execution is slipping, and the margin collapse is the issue. Management blamed external shocks (freight, COGS inflation); that's credible, but it doesn't excuse the miss on prior guidance or the lack of visibility into when recovery starts. The stock has priced in weakness (down 60% from ATH), which is appropriate given execution risk. H2 is the litmus test: prove margin stabilization, domestic acceleration, and regulated market momentum are real, or the long-term story loses air.

The number to track from here is organic EBITDA margin—not reported PAT, which can be obscured by non-operating items. Q3 margin (and PAT) must show stabilization toward 10%+ EBITDA and ₹40+ Cr PAT for the bull case to hold. Until then, hold and monitor; don't add on strength. The rating is Hold.

Informational and educational content only. Not investment advice.